Articles

Could High Drug Prices Be Bad for Innovation?

Industry leaders argue that high prices are necessary for innovation, but just how high do prices need to be?
Originally published on 10/23/2014 in Forbes: Cancer

Policymakers have been scrutinizing high drug prices like never before, and a series of six figure drugs are to blame.

The pharmaceutical industry has responded by stating these high prices are necessary to fuel the fire of innovation. But when does the potential to profit exceed that which is needed to drive innovation and pervert the market? Dr. Bach thinks we're already there.

Read the full article here.

Share

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

R&D Costs Do Not Explain Elevated U.S. Drug Prices
Drug prices in other high income countries for the 20 top selling drugs globally make up less than half of U.S. net drug prices.
HA Blog 03/07/2017
Could High Drug Prices Be Bad for Innovation?
Industry leaders argue that high prices are necessary for innovation, but just how high do prices need to be?
Forbes: Cancer 10/23/2014
Unpronounceable Drugs, Incomprehensible Prices
Cancer drug prices continue to rise. Just how much can pharmaceutical companies charge?
Forbes: Cancer 08/13/2014
The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.
Relentless Health Value 12/10/2020
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Drop in Cancer Deaths Reflect Failures of Our Society. Really.
Despite declining cancer death rates, the nation still presents societal failures to improve the state of our population's health.
The Boston Globe 02/21/2020
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now…
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
STAT News 10/11/2019
Time to Throw in the Towel on Biosimilars
Peter Bach and Mark Trusheim of MIT Sloan School of Management underscore the drawbacks of Washington's preferred solution to introduce competition for biologics, the biosimilar model.
The Wall Street Journal 08/21/2019
Mortgaging New Treatments Kicks the Can on High Drug Prices
The launch price for one-time gene therapy Zolgensma presents various implications.
Morning Consult 07/09/2019
A $475,000 price tag for a new cancer drug: crazy…
Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.
STAT News 08/31/2017

Featured News

See All News
The Wall Street Journal 12/06/2015

Price Bomb of Gilead

The liberals demanding pharmaceutical price controls, and the Republicans warming to the idea, have moved on from their outrage over the Hepatitis C cure that debuted two years ago.
Read Article
Newsletter

Stay up to date on our work and news